Cargando…
Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin
PEGL-DOX is an excellent treatment for recurrent ovarian cancer that rarely causes side-effects like cardiotoxicity or hair loss, but frequently results in Hand-Foot Syndrome (HFS). In severe cases, it can become necessary to reduce the PEGL-DOX concentration or the duration of the drug therapy, som...
Autores principales: | Yokomichi, Noriyuki, Nagasawa, Teruaki, Coler-Reilly, Ariella, Suzuki, Hiroyuki, Kubota, Yoshiki, Yoshioka, Ryosuke, Tozawa, Akiko, Suzuki, Nao, Yamaguchi, Yoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595474/ https://www.ncbi.nlm.nih.gov/pubmed/23386177 http://dx.doi.org/10.1007/s13577-012-0057-0 |
Ejemplares similares
-
Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
por: Yao, Shuyang, et al.
Publicado: (2021) -
Clinical Trial of Low Irritative Skin Care Cosmetics in Japanese Subjects with Dry Skin
por: Tanaka, Kazunori, et al.
Publicado: (2020) -
PEG-liposomal doxorubicin as a potential agent for canine metastatic osteosarcoma – in vitro and ex ovo studies
por: Walewska, Magdalena, et al.
Publicado: (2023) -
Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin
por: Nara, Katsuhiko, et al.
Publicado: (2023) -
Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish
por: Chen, Yau-Hung, et al.
Publicado: (2014)